SG11201701279VA - Alkylated influenza vaccines - Google Patents

Alkylated influenza vaccines

Info

Publication number
SG11201701279VA
SG11201701279VA SG11201701279VA SG11201701279VA SG11201701279VA SG 11201701279V A SG11201701279V A SG 11201701279VA SG 11201701279V A SG11201701279V A SG 11201701279VA SG 11201701279V A SG11201701279V A SG 11201701279VA SG 11201701279V A SG11201701279V A SG 11201701279VA
Authority
SG
Singapore
Prior art keywords
influenza vaccines
alkylated
alkylated influenza
vaccines
influenza
Prior art date
Application number
SG11201701279VA
Other languages
English (en)
Inventor
Brooke Milner
Jonathan Haines
Steven Hauser
Janet Poli
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of SG11201701279VA publication Critical patent/SG11201701279VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation
    • C12N2760/16063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201701279VA 2014-08-18 2015-08-18 Alkylated influenza vaccines SG11201701279VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462038753P 2014-08-18 2014-08-18
PCT/US2015/045689 WO2016028776A1 (en) 2014-08-18 2015-08-18 Alkylated influenza vaccines

Publications (1)

Publication Number Publication Date
SG11201701279VA true SG11201701279VA (en) 2017-03-30

Family

ID=54008038

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201701279VA SG11201701279VA (en) 2014-08-18 2015-08-18 Alkylated influenza vaccines

Country Status (9)

Country Link
US (1) US10124056B2 (enExample)
EP (1) EP3182998A1 (enExample)
JP (1) JP2017525766A (enExample)
KR (1) KR20170042605A (enExample)
CN (1) CN106794241A (enExample)
AU (1) AU2015305690A1 (enExample)
CA (1) CA2957570A1 (enExample)
SG (1) SG11201701279VA (enExample)
WO (1) WO2016028776A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7403733B2 (ja) * 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
WO2019045090A1 (ja) * 2017-09-04 2019-03-07 公益財団法人ヒューマンサイエンス振興財団 インフルエンザｈａスプリットワクチンの製造方法
CN111511800B (zh) 2017-10-30 2023-11-28 武田药品工业株式会社 灭活脂包膜病毒的环境相容性去污剂
TW202011986A (zh) 2018-07-23 2020-04-01 公益財團法人日本健康科學振興財團 包含流感疫苗之組合物
PH12021552094A1 (en) 2019-03-04 2022-05-30 Japan As Represented By Director General Of Nat Institute Of Infectious Diseases Method for preparing influenza ha split vaccine
CN112618709B (zh) * 2019-09-24 2023-11-03 华南理工大学 一种猪口服接种疫苗缓释佐剂及其制备方法与应用
CN112708599B (zh) * 2019-10-25 2022-02-18 中国农业大学 一株禽流感病毒疫苗株及其应用
US12428372B2 (en) 2022-04-14 2025-09-30 Saudi Arabian Oil Company ODSO acid medium, ODSO acid mixture medium, and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62221636A (ja) 1986-03-20 1987-09-29 Chemo Sero Therapeut Res Inst Ｂ型肝炎ウイルス抗原蛋白の可溶化方法
FR2773156B1 (fr) * 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
JPWO2003014338A1 (ja) 2001-08-02 2004-11-25 アンジェスＭｇ株式会社 不活性化ウイルスエンベロープの製造方法
EP1481985A1 (en) 2003-05-28 2004-12-01 Innogenetics N.V. Modified hepatitis C virus (HCV) NS3 for medical treatment
DK1725581T3 (da) * 2004-03-17 2008-11-10 Crucell Holland Bv Ny assay til adskillelse og kvantificering af hæmagglutinin-antigener
GB0502901D0 (en) * 2005-02-11 2005-03-16 Nat Inst Biological Standards & Control New detoxification method
CN101161285A (zh) * 2007-09-06 2008-04-16 上海荣盛生物技术有限公司 流感病毒裂解疫苗
CN102858961A (zh) 2010-05-03 2013-01-02 葛兰素史密丝克莱恩生物有限公司 新方法
WO2011154976A2 (en) 2010-06-08 2011-12-15 Panacea Biotec Limited Improved influenza vaccine
CN102406931B (zh) * 2011-11-25 2014-02-05 成都康华生物制品有限公司 大流行流感病毒裂解疫苗

Also Published As

Publication number Publication date
US20160045590A1 (en) 2016-02-18
CA2957570A1 (en) 2016-02-25
WO2016028776A1 (en) 2016-02-25
EP3182998A1 (en) 2017-06-28
JP2017525766A (ja) 2017-09-07
KR20170042605A (ko) 2017-04-19
US10124056B2 (en) 2018-11-13
CN106794241A (zh) 2017-05-31
AU2015305690A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
GB201410971D0 (en) Vaccine
GB201518684D0 (en) Vaccine
GB201406608D0 (en) Virus
PL3185899T3 (pl) Wzmocniona szczepionka wektorowa-hvt przeciwko nd-ibd
SG11201707926WA (en) Streptococcal vaccine
SG11201610946YA (en) Meningococcus vaccines
SG11201701279VA (en) Alkylated influenza vaccines
IL248223B (en) Compositions of vaccine
IL247159B (en) Components of pcsk9
GB201522132D0 (en) Vaccine
GB201419572D0 (en) Virus
GB201616904D0 (en) Vaccine
GB201608821D0 (en) Vaccines
GB201419736D0 (en) Secure id labeling
SMT202000589T1 (it) Vaccino
SI3193923T1 (sl) Adjuvansi
GB201419061D0 (en) Conjugated Vaccine
GB201417379D0 (en) Comparator
GB201402083D0 (en) Retaining means
ZA201702925B (en) New immunostimulatory compounds
GB201417214D0 (en) Vaccine
GB201603029D0 (en) Vaccine
GB201406628D0 (en) Vaccine
GB2522661B (en) Context configuration
GB201614387D0 (en) Improved vaccines